Cancer Therapy News and Research

RSS

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

Younger breast cancer survivors face more serious mental issues

Quality of life in younger patients treated for breast cancer is seriously compromised and these women suffer from severe psychological distress, infertility, premature menopause, a decrease in physical activity and weight gain, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

24 Jan 2012

Haymarket Media launches ChemotherapyAdvisor.com

Haymarket Media Inc., publisher of Monthly Prescribing Reference (MPR), MPR Hematology/Oncology Edition, and Oncology Nurse Advisor (ONA), is pleased to announce the launch of ChemotherapyAdvisor.com, offering oncologists and their support teams a unique clinical decision support tool.

23 Jan 2012

Study describes new pharmacological resistance to colon cancer

Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR.

23 Jan 2012

Younger women with breast cancer experience a decrease in health-related QOL

Younger women with breast cancer experience a decrease in their health-related quality of life (QOL), associated with increased psychological distress, weight gain, a decline in their physical activity, infertility and early onset menopause, according to a study published January 20 in the Journal of the National Cancer Institute.

21 Jan 2012

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

20 Jan 2012

Novel nano-carrier platform shows promise for cancer drug delivery

A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published online in Angewandte Chemie, a leading international chemistry journal.

20 Jan 2012

Scientists decode unknown mechanism of imiquimod in tumour defense

A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.

20 Jan 2012

HOXB13 gene mutation linked to familial prostate cancer risk

The quest for genetic information in the fight against prostate cancer is nearly two decades long. While researchers and doctors have long accepted the hereditary nature of the disease, in that closer relatives are at a two-fold increased risk of developing prostate cancer, the genetic explanation remained a mystery. Last week geneticists shared news of a novel gene mutation linked to familial prostate cancer risk.

19 Jan 2012

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.

18 Jan 2012

Scientists identify pathway that activates hepsin on the surface of breast tumor cells

Scientists from the University of Helsinki and from UCSF have exposed a cell pathway that breast tumor cells use to destruct local tissue neighborhood. Cancer cells may use this pathway to free themselves from mammary epithelial tissue architecture, to spread to surrounding tissues. The cell pathway, the researchers found, is a biochemical chain of events leading to activation of a protein-cleaving enzyme on the surface of the tumor cells.

18 Jan 2012

Viewpoints: Health care is a civil right; A Medicare strategy based on Lenin

Martin Luther King Jr.'s legacy is one of progress toward a better life for every American, including equal opportunity in voting, housing, education, and employment. Reflecting on his legacy also means recognizing the steps we must take to address the inequalities that persist. Many of these involve health care. Poor and minority Americans suffer from more preventable diseases on average, lower-quality care, fewer treatment options, and less health insurance coverage.

18 Jan 2012

New combination treatment more effective in treating cutaneous T-Cell lymphoma

Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.

18 Jan 2012

Scientists use gold-filled silicon wafers to target and burn breast cancer cells

By shining infrared light on specially designed, gold-filled silicon wafers, scientists at The Methodist Hospital Research Institute have successfully targeted and burned breast cancer cells. If the technology is shown to work in human clinical trials, it could provide patients a non-invasive alternative to surgical ablation, and could be used in conjunction with traditional cancer treatments, such as chemotherapy, to make those treatments more effective.

18 Jan 2012

Study explains how cells regulate their bonds during new blood vessel development

New research explains how cells regulate their bonds during the development of new blood vessels. For the first time, the role of the protein Raf-1 in determining the strength of the bond between cells has been shown.

18 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Study compares adoptive T-cell therapy with drug-based cancer treatment

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.

18 Jan 2012

Scientists identify hepsin protein's role in breast cancer

Cancers rarely are deadly unless they evolve the ability to grow beyond the tissues in which they first arise. Normally, cells -- even early-stage tumor cells -- are tethered to scaffolding that helps to restrain any destructive tendencies. But scientists from the University of Helsinki, Finland, and from UCSF have identified a cleaver-wielding protein that frees some tumor cells, allowing them to further misbehave.

18 Jan 2012

State roundup: State lawmakers, governors planning health legislation; Some Pa. kids losing Medicaid

Iowa House and Senate Republicans could support legislation requiring lawmakers to contribute to the cost of their state-provided health-care benefits, party leaders told the Des Moines Register's editorial board this morning. The health-care packages now offered by the state - in which most employees, including legislators, are not required to make contributions from their salaries - are "out of touch" with the plans available to average Iowans, ... House Speaker Kraig Paulsen, R-Hiawatha, said.

18 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012